Gerald Batist

Generating author description...

All published works

Action	Title	Year	Authors
+	The importance of greater speed in drug development for advanced malignancies	2018	David J. Stewart Andrew A. Stewart Paul Wheatley‐Price Gerald Batist Hagop M. Kantarjian Joan H. Schiller Mark Clemons John‐Peter Bradford Laurel Gillespie Razelle Kurzrock
+ PDF Chat	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial	2015	Jordi Rodón Jean‐Charles Soria Raanan Berger Gerald Batist Apostolia M. Tsimberidou Catherine Bresson J. Jack Lee Eitan Rubin Amir Onn Richard L. Schilsky
+	Redefining cancer: a new paradigm for better and faster treatment innovation.	2014	David J. Stewart Gerald Batist
+ PDF Chat	In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer	2011	Sunil Verma Deanna McLeod Gerald Batist André Robidoux Ilidio Martins John R. Mackey

Common Coauthors

Coauthor	Papers Together
David J. Stewart	2
Razelle Kurzrock	2
Jean‐Charles Soria	1
Ilidio Martins	1
Jordi Rodón	1
Richard L. Schilsky	1
John R. Mackey	1
Laurel Gillespie	1
Apostolia M. Tsimberidou	1
Wilson H. Miller	1
Joan H. Schiller	1
Paul Wheatley‐Price	1
Alexander M.M. Eggermont	1
Catherine Bresson	1
Raanan Berger	1
Amir Onn	1
John‐Peter Bradford	1
Mark Clemons	1
Hagop M. Kantarjian	1
J. Jack Lee	1
Andrew A. Stewart	1
Sunil Verma	1
André Robidoux	1
John Mendelsohn	1
Vladimir Lazar	1
Deanna McLeod	1
Eitan Rubin	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies	2004	David R. Newell Jernej Silvester Cathy McDowell S S Burtles	2
+ PDF Chat	Fool’s gold, lost treasures, and the randomized clinical trial	2013	David J. Stewart Razelle Kurzrock	2
+	Developing Standards for Breakthrough Therapy Designation in Oncology	2013	Sandra J. Horning Daniel A. Haber Wendy Selig S. Percy Ivy Samantha Roberts Jeff Allen Ellen V. Sigal Charles L. Sawyers	2
+	Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial	2009	Apostolia M. Tsimberidou Fadi Braiteh David J. Stewart Razelle Kurzrock	2
+ PDF Chat	Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research	2010	David J. Stewart Simon N. Whitney Razelle Kurzrock	2
+ PDF Chat	Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics	1999	David R. Newell S S Burtles B.W. Fox Duncan I. Jodrell T. A. Connors	2
+	Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007	2010	R. Sridhara John R. Johnson Robert Justice Patricia Keegan Aloka Chakravarty Richard Pazdur	1
+	End Points and United States Food and Drug Administration Approval of Oncology Drugs	2003	John R. Johnson Grant Williams Richard Pazdur	1
+ PDF Chat	Experimental designs for small randomised clinical trials: an algorithm for choice	2013	Catherine Cornu Behrouz Kassaï Roland Fisch Catherine Chiron Corinne Alberti Renzo Guerrini Anna Rosati Gérard Pons Harm Tiddens Sylvie Chabaud	1
+	Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues	2008	Aloka Chakravarty Rajeshwari Sridhara	1
+ PDF Chat	Accelerated Approval of Oncology Products: A Decade of Experience	2004	Ramzi Dagher John R. Johnson Grant Williams Patricia Keegan Richard Pazdur	1
+	Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III	2008	Robert H. El-Maraghi Elizabeth A. Eisenhauer	1
+	Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group B	2006	David M. Dilts Alan B. Sandler Matthew J. Baker Steven K. Cheng Stephen L. George Kathleen S. Karas Stephen McGuire Gourija S. Menon Jason Reusch Debbie Sawyer	1
+	Proposal for the Use of Progression-Free Survival in Unblinded Randomized Trials	2007	Boris Freidlin Edward L. Korn Sally Hunsberger Robert J. Gray Scott Saxman Jo Anne Zujewski	1
+	Data collection in cancer clinical trials: Too much of a good thing?	2013	Erin O’Leary Hsien Seow Jim A. Julian Mark N. Levine Gregory R. Pond	1
+	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative	2012	Apostolia M. Tsimberidou Nancy G. Iskander David S. Hong Jennifer J. Wheler Gerald S. Falchook Siqing Fu Sarina A. Piha‐Paul Aung Naing Filip Janků Rajyalakshmi Luthra	1
+ PDF Chat	Progression-free survival as a surrogate endpoint in advanced breast cancer	2008	Rebecca A. Miksad Vera Zietemann R Gothe Ruth Schwarzer Annette Conrads‐Frank Petra Schnell-Inderst Björn Stollenwerk Uwe Siebert	1
+	Redefining cancer: a new paradigm for better and faster treatment innovation.	2014	David J. Stewart Gerald Batist	1
+	I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy	2009	AD Barker C C Sigman Kelloff Gj NM Hylton DA Berry L. Esserman	1
+	The importance of greater speed in drug development for advanced malignancies	2018	David J. Stewart Andrew A. Stewart Paul Wheatley‐Price Gerald Batist Hagop M. Kantarjian Joan H. Schiller Mark Clemons John‐Peter Bradford Laurel Gillespie Razelle Kurzrock	1
+ PDF Chat	Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review	2008	Andrea Takeda Emma Loveman P Harris D Hartwell Karen Welch	1
+ PDF Chat	Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group	2008	David M. Dilts Alan Sandler Steven K. Cheng Joshua S. Crites L Ferranti Amy Wu Robert J. Gray Jean MacDonald Donna M. Marinucci Robert L. Comis	1
+ PDF Chat	Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence	2014	Christopher M. Booth Ian F. Tannock	1
+ PDF Chat	The changing face of Phase 1 cancer clinical trials	2009	Barbara S. Craft Razelle Kurzrock Xiudong Lei Roy S. Herbst Scott M. Lippman Siqing Fu Daniel D. Karp	1
+ PDF Chat	Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?	2009	Elizabeth A. Richey Erica Lyons Jonathan R. Nebeker Veena Shankaran June M. McKoy Thanh Ha Luu Narissa J. Nonzee Steven Trifilio Oliver Sartor Al B. Benson	1